Rituximab for first or relapsing psychosis with autoantibodies
Part of Mental health clinical trials.
This Phase 3 study tests rituximab, an immune-focused medicine, for people with a first episode or relapse of psychosis who have specific brain-targeting autoantibodies in their blood. It may help calm symptoms by changing how the immune system contributes to the illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a first episode or a relapse of psychosis (not a long-term chronic stable psychosis)
- Blood tests show specific harmful autoantibodies related to the brain and nervous system
- You meet symptom severity scoring requirements (MDC score greater than 3 for the next study step)
- You can take immune-suppressing treatment safely (no major active infections or severe immune problems)
- Blood counts are high enough (platelets at least 75, and neutrophils at least 1.5)
- You have a normal heart tracing (ECG) if you’ve had heart disease before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests rituximab (an immune system medicine) to see if it can reduce OCD symptoms and/or psychosis when there are signs the immune system may be involved. You may be considered if other standard psychiatric treatments have not helped enough and your illness seems relatively recent with possible inflammation clues.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This trial tests if rituximab, a targeted immune therapy, can help people with a newly identified antibody-linked condition. You may qualify if you have positive anti-vimentin antibodies in spinal fluid and signs of active disease such as new MRI lesions or worsening symptoms.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This trial tests rituximab, a medicine that affects the immune system, in children who have their first episode of steroid-sensitive nephrotic syndrome and are in remission at enrollment. It aims to see whether rituximab helps prevent relapse and improves kidney outcomes with fewer steroid needs.
This study looks at the levels of rituximab (a medicine that calms the immune system) and your body's response to it in people with certain autoimmune diseases. It may help doctors understand how to better adjust treatment.
Hear when a new Mental Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.